Equitoxicity of bolus and infusional etoposide: Results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

Annals of Hematology

Volumn 87, Issue 9, 2008, Pages 717-726

  Zwick, Carsten ^a   Birkmann, Josef ^b   Peter, Norma ^c   Bodenstein, Heinrich ^d   Fuchs, Roland ^e   Hänel, Mathias ^f   Reiser, Marcel ^g   Hensel, Manfred ^h   Clemens, Michael ⁱ   Zeynalova, Samira ^j   Ziepert, Marita ^j   Pfreundschuh, Michael ^a,k  

^a SAARLAND UNIVERSITY   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c CARL THIEM KLINIKUM   (Germany)

^d KLINIKUM MINDEN   (Germany)

^e ST ANTONIUS HOSPITAL ESCHWEILER   (Germany)

^f KLINIKUM CHEMNITZ   (Germany)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ Mütterhaus   (Germany)

^j UNIVERSITY OF LEIPZIG   (Germany)

^k DSHNHL Secretariat   (Germany)

more..

Author keywords

Aggressive lymphoma; Chemotherapy; Continuous infusion; Relapse

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER DISEASE; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLITIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GERMANY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; LABORATORY TEST; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS; LEUKOCYTE COUNT; LYMPHATIC METASTASIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM STAGING; PLATELET COUNT; PREDNISONE; SURVIVAL ANALYSIS;

EID: 48649099529     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0500-1     Document Type: Article

References (51)

1. Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C (1985) Pharmacology of mitoxantrone: Mode of action and pharmacokinetics. Invest New Drugs 3:101-107
2. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693-697
3. Chao NJ, Rosenberg SA, Horning SJ (1990) CEPP(B): An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 76:1293-1298
4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
5. Child JA, Johnson SA, Rule S, Smith GM, Morgan GJ, Johnson PW, Prentice AG, Tollerfield SM, Wareham E (2000) FLUDAP: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 37:309-317
6. Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PW, Reznek R, Masud T, Gregory W, Wrigley PF (1994) A randomized trial of two etoposide schedules in small-cell lung cancer: The influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12(7):1427-1435
7. Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R (2004) Gemcitabine, dexamethasone and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101:1835-1842
8. Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, Maksymiuk A, Hoskins P, Matthews S, Eisenhauer E (2002) Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: A National Cancer Institute of Canada Clinical Trials Group study. Leuk Lymphoma 43:1581-1587
9. De Lord C, Newland AC, Linch DC, Vaughan HB, Vaughan HG (1992) Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma. Hematol Oncol 10:81-86
10. Drewinko M, Barlogie B (1976) Survival and cell cycle progression delay of human lymphoma cells in vitro exposed to VP-16. Cancer Treat Rep 60:1295-1306
11. El Gnaoui T, Dupuis J, Joly B, Belhadj K, Rahmouni A, Copie-Bergman C, Allain A, Tabah-Fisch I, Reyes F, Haioun C (2005) Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma, a single institution pilot study. (abstract). Ann Oncol 15(Supplement 5):182
12. Enblad G, Hagberg H, Glimelius B (1996) Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: A Swedish national prospective study. Swedish Lymphoma Study Group. Acta Oncol 35:165-170
13. Ezzat AA, Khalifa F, Berry J, Khan B, Raja MA, Abdel-Warith A (1994) E-SHAP: An effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. Ann Oncol 5:453-456
14. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
15. Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, Prince HM, Pantolony D, Keating A, Crump M (1997) Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 8:675-680
16. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH. J Clin Oncol 18:3633-3642
17. Haim N, Ben Shahar M, Faraggi D, Tsuri-Etzioni A, Leviov M, Epelbaum R (1997) Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma. Cancer 80:1989-1996
18. Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F, Hanel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR (2002) Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 81:96-102
19. Haq R, Sawka CA, Franssen E, Berinstein NL (1999) Mitoxantrone-DHAP with GM-CSF: An active but myelosuppressive salvage therapy for relapsed/ refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 35:527-536
20. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
21. Hill BT, Whelan RD, Rupniak HT, Dennis LY, Rosholt MA (1981) A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Pharmacol 7:21-26
22. Hill BT, Dennis LY, Li XT, Whelan RD (1985) Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Cancer Chemother Pharmacol 14:194-201
23. Kaplan EL, Meier R (1958) Nonparametric estimation from incomplete observations. (abstract). J Am Stat Assoc 53:457-481
24. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636
25. Ludwig R, Alberts DS, Miller TP, Salmon SE (1984) Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay. Cancer Chemother Pharmacol 12(3):135-141
26. Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F (1996) High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study. J Clin Oncol 14:534-542
27. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE (1976) Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493
28. Mey UJ, Olivieri A, Orlopp KS, Rabe C, Strehl JW, Gorschlueter M, Hensel M, Flieger D, Glasmacher AG, Schmidt-Wolf IG (2006) DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: A matched-pair analysis. Leuk Lymphoma 47:2558-2566
29. Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschluter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschutz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG (2006) Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 24:593-600
30. Meyer RM, Hryniuk WM, Goodyear MD (1991) The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 9:339-347
31. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD (1999) Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17:3776-3785
32. Nuckel H, Durig J, Duhrsen U (2003) Salvage chemotherapy according to the ASHAP protocol: A single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas. Ann Hematol 82:481-486
33. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641
34. Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545
35. Press OW, Livingston R, Mortimer J, Collin C, Appelbaum F (1991) Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high- dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9:423-431
36. Reiser M, Josting A, Dias WP, Draube A, Scheid C, Tesch H, Wolf J, Diehl V, Engert A (1999) Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 33:305-312
37. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734-1741
38. Rodriguez-Monge EJ, Cabanillas F (1997) Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 11:937-947
39. Rybak ME, McCarroll K, Kaplan RJ, Propert KJ, Budman DR, Gottlieb AJ (1990) Phase II trial of etoposide and cis-diaminodichloro-platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and Leukemia Group B (CALGB) Study 8353. Med Pediatr Oncol 18:177-180
40. Seymour JF, Grigg AP, Szer J, Fox RM (2002) Cisplatin, fludarabine, and cytarabine: A novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 94:585-593
41. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregoray WM, Lowe DG, Reznek RH, Wrigley PF (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7(9):1333-1340
42. Soussain C, Souleau B, Gabarre J, Zouabi H, Sutton L, Boccaccio C, Albin N, Charlotte F, Merle-Beral H, Delort J, Binet JL, Leblond V (1999) Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Leuk Lymphoma 33:543-550
43. Sparano JA, Wiernik PH, Leaf A, Dutcher JP (1993) Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 11:1071-1079
44. Sweetenham JW, Johnson PW (1994) ESHAP chemotherapy for relapsed/ refractory non-Hodgkin's lymphoma. J Clin Oncol 12:2766
45. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117-122
46. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F (1994) ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 12:1169-1176
47. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD (1993) EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582
48. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 99:2685-2693
49. Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML (2002) The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29:41-47
50. Yap HY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP (1981) Dihydroxyanthracenedione: A promising new drug in the treatment of metastatic breast cancer. Ann Intern Med 95:694-697
51. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH (2003) Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 14(Suppl 1):I5-I10